Published Research and Presentations

177 Lu-PSMA-617 with ipilimumab and nivolumab in metastatic castration-resistant prostate cancer (mCRPC): an investigator-initiated phase 2 trial

EVOLUTION

ASCO 2025

02/06/2025

Shahneen Sandhu

Mitomycin plus (BCG), as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase 3 trial (ANZUP 1301)

BCG+MM

ASCO 2025

02/06/2025

Dickon Hayne

Louise Emmett, Shalini Subramaniam, Megan Crumbaker, Andrew Nguyen, Anthony M. Joshua, Andrew James Weickhardt, Sze Ting Lee, Siobhan Ng, Roslyn J. Francis, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian David Kirkwood, Shahneen Sandhu, Alison Yan Zhang, Michael S. Hofman, Hayley Thomas, Andrew James Martin, Ian D. Davis, and Martin R Stockler, The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

Megan Crumbaker, Laurence Krieger, David Pook, Ian D. Davis, Chris Oldmeadow, Joshua Hurwitz , Andrisha Inderjeeth, Haryana Dhillon, Teesha Downton, Gavin Marx, Samantha Shekar, Emmanuel S. Antonarakis, Samuel Denmeade, Angelyn Anton, Hsiang Tan, Sharad Sharma, Jeff Goh, Antoinette Fontela, Lisa Horvath, Anthony M. Joshua

B Mak, B Tran, H Thomas, FD Pashankar, AR Hansen, DR Feldman, RA Huddart, M Wheater, E Dunwoodie, D Mazhar, NJ Lawrence, AG Stevanovic, AJ Birtle, O Oladipo, D Wyld, JM Balagtas, MR Stockler, PS Grimison, Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Lisa G Horvath, Hui-Ming Lin, Ian D Davis, Andrew J Martin, Tahlia Scheinberg, Neil Portman, Peter J Meikle, Kevin Huyn, Anthony Joshua, Margaret McJannett, Vinod Subhash, Sonia Yip, Scott A North, Raymond S McDermott, Kim N Chi, Martin R Stockler, Christopher Sweeney for the ENZAMET trial investigators on behalf of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).